PKCtheta-CD28 interaction: A novel drug target for autoimmunity and inflammation

PKCtheta-CD28 相互作用：自身免疫和炎症的新型药物靶点

• 批准号: 8609477
• 负责人: Elizabeth Yan Zhang
• 金额: $ 5.33万
• 依托单位: LA JOLLA INSTITUTE FOR IMMUNOLOGY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-02-01 至 2016-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8609477
• 关键词: Address; Allergic Disease; American; Antigens; Autoimmune Diseases; Autoimmune Process; Autoimmune Responses; Autoimmunity; Biological; Bone Marrow; CD28 gene; Cell Surface Receptors; Cells; Chronic; Colitis; Communicable Diseases; Complex; Crohn' s disease; Data; Development; Diagnosis; Disease; Disease model; Dissection; Dominant-Negative Mutation; Drug Targeting; Effector Cell; Enzymes; Family member; Immune System Diseases; Immune response; Immune system; Immunity; Immunosuppression; In Vitro; Inflammation; Inflammatory; Inflammatory Response; Insulin-Dependent Diabetes Mellitus; Knowledge; Laboratories; Lead; Mediating; Mentors; Mission; Modeling; Molecular; Multiple Sclerosis; Mus; National Institute of Allergy and Infectious Disease; National Institute of Diabetes and Digestive and Kidney Diseases; Play; Population; Protein Kinase C; Proteins; Recruitment Activity; Regulatory T-Lymphocyte; Research Support; Rheumatoid Arthritis; Role; T cell response; T-Cell Activation; T-Lymphocyte; Testing; Th1 Cells; Therapeutic; Transgenic Mice; Virus; Work; allograft rejection; base; design; differentiation retarding activity; immunological synapse; in vivo; inhibitor/antagonist; leukemia; mutant; novel; novel strategies; novel therapeutics; prevent; public health relevance; receptor; response; small molecule; tool

DESCRIPTION (provided by applicant): Approximately 50 million Americans suffer from ~100 known autoimmune diseases (e.g., type I diabetes, Crohn's disease, and rheumatoid arthritis). The proposed studies focus on the impact of a novel TCR-induced interaction between protein kinase C-theta (PKC?) and CD28 on different aspects of immune responses and its implication for treating autoimmune and inflammatory diseases. PKC? is a Ca2+-independent PKC family member that is most abundantly expressed in T cells, and its critical role in conventional T cell activation and survival has been well documented. In vivo studies revealed the selective role of PKC? in different types of immunity. In particular, a recent study showed that in sharp contrast to T effector (Teff) cells, PKC? is excluded from the immunological synapse (IS) of induced regulatory T (iTreg) cells and, moreover, it inhibits their suppressive function. These findings point to the high promise of PKC? as a selective drug target for immunosuppression of T cell-mediated autoimmunity and inflammation. My preliminary data demonstrated that blocking the PKC?-CD28 association by different strategies promoted the differentiation and suppressive function of Treg cells. Here, I will test the hypothesis that blockade of the PKC?-CD28 interaction inhibits the differentiation and activity of pathogenic T cells and promotes the functin of Treg cells, thereby achieving a beneficial synergetic effect against T cell-mediated autoimmune and inflammatory responses. I will use two novel and highly specific complementary tools, i.e., i) blockade of the inducible PKC?-CD28 interaction by a dominant negative PKC? V3-based mutant; and ii) small molecule allosteric compounds generated by our collaborators that I found to inhibit this interaction. In Aim 1, I will analyze the effect of thes strategies on Teff and Treg differentiation and function in vitro, and in Aim 2, I will evaluate th impact of blocking the PKC?-CD28 interaction on an experimental disease model of chronic colitis in mice. The results of this project will reveal the effects of sequestering PKC? from CD28 and the IS on Treg and Teff differentiation and function and uncover a promising novel approach for treating T cell-mediated experimental inflammatory disease, i.e., Th17-mediated colitis. Collectively, this study is likely to pave the way for the development of new, highly selective therapeutic strategies to treat T cell-mediated autoimmunity and inflammation. This project fits seamlessly with the NIAID mission to conduct and support research to study the causes of allergic, immunologic, and infectious diseases, and to develop better means of preventing, diagnosing, and treating these illnesses. Meanwhile, this project also has close relevance to the mission of the NIDDK as it will study the effects of blocking the PKC?-CD28 interaction on an experimental chronic colitis model.

描述（由申请人提供）：大约5000万美国人患有约100种已知的自身免疫性疾病（例如，I型糖尿病、克罗恩病和类风湿性关节炎）。拟议的研究集中在蛋白激酶C-θ（PKC？）和CD 28对免疫应答的不同方面的作用及其对治疗自身免疫性和炎性疾病的意义。PKC？是一种钙离子非依赖性PKC家族成员，在T细胞中表达最丰富，其在常规T细胞活化和存活中的关键作用已被充分证明。在体内研究揭示了PKC的选择性作用？不同类型的免疫力。特别是，最近的一项研究表明，在形成鲜明对比的T效应（Teff）细胞，PKC？从诱导的调节性T（iTreg）细胞的免疫突触（IS）中排除，并且，它抑制它们的抑制功能。这些发现表明PKC？作为T细胞介导的自身免疫和炎症的免疫抑制的选择性药物靶标。我的初步数据显示阻断蛋白激酶C？-不同策略的CD 28结合促进了Treg细胞的分化和抑制功能。在这里，我将测试的假设，封锁的PKC？- CD 28相互作用抑制致病性T细胞的分化和活性并促进Treg细胞的功能，从而实现对抗T细胞介导的自身免疫和炎症反应的有益协同作用。我将使用两个新颖的和高度具体的补充工具，即，i）阻断诱导型PKC？- CD 28与显性负性PKC的相互作用？基于V3的突变体;和ii）我们的合作者产生的小分子变构化合物，我发现它们可以抑制这种相互作用。在目标1中，我将分析这些策略对Teff和Treg体外分化和功能的影响，在目标2中，我将评估阻断PKC？CD 28在小鼠慢性结肠炎实验疾病模型上的相互作用。该项目的结果将揭示隔离PKC？来自cd 28 以及IS对Treg和Teff分化和功能的影响，并揭示了治疗T细胞介导的实验性炎性疾病的有希望的新方法，即，Th 17介导的结肠炎。总的来说，这项研究可能为开发新的，高选择性的治疗策略来治疗T细胞介导的自身免疫和炎症铺平道路。该项目与NIAID的使命完美契合，即开展和支持研究，以研究过敏性、免疫性和传染性疾病的原因，并开发更好的预防、诊断和治疗这些疾病的方法。同时，该项目也与NIDDK的使命密切相关，因为它将研究阻断PKC？实验性慢性结肠炎模型上的CD 28相互作用。